PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Status:
Recruiting
Trial end date:
2022-09-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether a drug called PDR001, combined with either
trametinib or dabrafenib, is a safe and effective treatment for thyroid cancer.